TARIS Biomedical is a pharmaceutical company focused on developing targeted therapies for difficult-to-treat bladder diseases and other urologic conditions
TARIS Biomedical is a pharmaceutical company focused on developing targeted therapies for difficult-to-treat bladder diseases and other urologic conditions. Its investigational product TAR-200 has been evaluated in clinical trials, including in combination with nivolumab for muscle-invasive bladder cancer.